Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:56:43.935Z.
Calculation as of: 2026-10-06T16:56:43.935Z.
Quote observation: 2026-10-06T15:59:37.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 787788ea5c712995087b0511470a3bc1500b131fb4a88c1f5ff44ca2612ce4c8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$51.33M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$50.36M
EV/EBIT Ratio
N/A
TTM Avg
36.45x
3Y Avg
39.02x
5Y Avg
39.02x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| eXoZymes, Inc. (EXOZ) | $51.42M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $51.33M | N/A | N/A | N/A | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.33M | N/A | N/A | N/A | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $51.60M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $51.61M | 11.46x | 6.17x | 6.96x | 6.04x |
| Celularity Inc. (CELU)vs › | $50.66M | N/A | N/A | N/A | N/A |
| Clene Inc. (CLNN)vs › | $50.54M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $50.45M | N/A | N/A | N/A | N/A |
| Microbot Medical Inc. (MBOT)vs › | $50.36M | N/A | 36.45x | 39.02x | 39.02x |
| INmune Bio, Inc. (INMB)vs › | $50.25M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute